Peptide R18H from BRN2 transcription factor POU domain displays antitumor activity in vitro and in vivo and induces apoptosis in B16F10-Nex2 cells
ARTIGO
Inglês
Agradecimentos: We thank Prof. Dr. Edgar J. P. Gamero from Federal University of Mato Grosso do Sul for the nontumor J774 1.6, Prof. Dr. Júlio Scharfstein from Federal University of Rio de Janeiro for the nontumor HUVEC and Prof. Dr. Luis F. Lima Reis, Hospital Sirio Li
BRN2 transcription factor is associated with the development of malignant melanoma. The cytotoxic activities and cell death mechanism against B16F10-Nex2 cells were determined with synthetic peptide R18H derived from the POU domain of the BRN2 transcripti
CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ
FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP
2015/05980-9; 2014/21129-4
fechado
Peptide R18H from BRN2 transcription factor POU domain displays antitumor activity in vitro and in vivo and induces apoptosis in B16F10-Nex2 cells
Peptide R18H from BRN2 transcription factor POU domain displays antitumor activity in vitro and in vivo and induces apoptosis in B16F10-Nex2 cells
Fontes
|
Anti-cancer agents in medicinal chemistry supl 3, no. 19 (2019), p. 389-401 |